na your alright... huntley (realativley consrvative) values them at $1.15 with a strong probability of being taken over in next 6 - 12 months for $1.50 to $1.75 Huntley is the lowest of the serious evaluations that i have seen... except bioshares... but i think they been hitten the drugs themselves (mind you havent actually read / seen their report itself)